Acumen Pharmaceuticals will present one oral and two poster sessions at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Copenhagen from March 17-21, 2026. These presentations will cover sabirnetug brain delivery enhancements, biomarker treatment responses and novel AβO-targeting antibodies.

The oral presentation on March 21 will detail enhanced brain delivery of sabirnetug after fusion with an anti-transferrin receptor antibody fragment in a mouse model, leveraging JCR Pharmaceuticals’ transferrin-receptor-targeting J-Brain Cargo® platform. This data underscores the ongoing collaboration aimed at improving central nervous system penetration and safety profile.

One poster will report exploratory evaluation of the NULISA-Seq™ CNS disease panel, tracking CSF- and blood-based biomarkers to assess sabirnetug treatment effects. The second poster will describe the development and characterization of highly selective antibodies against toxic soluble amyloid β oligomers.

Sabirnetug (ACU193) is a humanized monoclonal antibody with Fast Track designation for early Alzheimer’s disease and is being evaluated in the Phase 2 ALTITUDE-AD trial that has enrolled 542 patients. Acumen is also exploring a subcutaneous formulation using ENHANZE® technology to broaden delivery options.